ES2134361T3 - Compuestos de cromano neuroprotectores. - Google Patents

Compuestos de cromano neuroprotectores.

Info

Publication number
ES2134361T3
ES2134361T3 ES94931668T ES94931668T ES2134361T3 ES 2134361 T3 ES2134361 T3 ES 2134361T3 ES 94931668 T ES94931668 T ES 94931668T ES 94931668 T ES94931668 T ES 94931668T ES 2134361 T3 ES2134361 T3 ES 2134361T3
Authority
ES
Spain
Prior art keywords
chroman
neuroprotectors
compounds
treatment
pharmaces
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931668T
Other languages
English (en)
Inventor
Todd W Butler
Bertrand L Chenard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2134361T3 publication Critical patent/ES2134361T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

3R * 4S * 3-[4-(4-FLUOFENIL)-4-HIDROXI-PIPERIDIN-1-IL]CROMAN-4,7-DIOL, SUS ENANTIOMEROS Y SALES FARMACEUTICAMENTE ACEPTABLES SON AGENTES ORALES EFECTIVOS PARA EL TRATAMIENTO DE ENFERMEDADES Y CONDICIONES SUSCEPTIBLES AL TRATAMIENTO MEDIANTE FARMACOS DE BLOQUEO NMDA.
ES94931668T 1994-01-31 1994-11-21 Compuestos de cromano neuroprotectores. Expired - Lifetime ES2134361T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31

Publications (1)

Publication Number Publication Date
ES2134361T3 true ES2134361T3 (es) 1999-10-01

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931668T Expired - Lifetime ES2134361T3 (es) 1994-01-31 1994-11-21 Compuestos de cromano neuroprotectores.

Country Status (27)

Country Link
US (1) US5744483A (es)
EP (1) EP0741724B1 (es)
JP (1) JP2866743B2 (es)
CN (1) CN1048247C (es)
AT (1) ATE183184T1 (es)
AU (1) AU684568B2 (es)
BR (2) BR9408506A (es)
CA (1) CA2182101C (es)
CO (1) CO4230161A1 (es)
CZ (1) CZ286757B6 (es)
DE (1) DE69420053T2 (es)
DK (1) DK0741724T3 (es)
EG (1) EG20672A (es)
ES (1) ES2134361T3 (es)
FI (1) FI113769B (es)
GR (1) GR3031356T3 (es)
HU (1) HU221633B1 (es)
IL (1) IL112415A (es)
MY (1) MY111623A (es)
NO (1) NO309190B1 (es)
NZ (1) NZ275151A (es)
PE (1) PE43795A1 (es)
PL (1) PL179448B1 (es)
RU (1) RU2126404C1 (es)
TW (1) TW449591B (es)
WO (1) WO1995020587A1 (es)
ZA (1) ZA95692B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509839A (ja) * 1995-09-15 1999-08-31 ファイザー・インコーポレーテッド 薬剤活性を有するフェノール誘導体
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
PT1408964E (pt) * 2001-07-26 2007-05-31 Merck Patent Gmbh Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis.
RU2240113C1 (ru) * 2003-01-23 2004-11-20 Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова Способ экстренной медикаментозной помощи при острой травме спинного мозга
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
CA2628173A1 (en) 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
RU2418578C1 (ru) * 2009-12-08 2011-05-20 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (es) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (fr) * 1978-07-03 1980-02-07 Sandoz Ag Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0076075B1 (en) * 1981-09-25 1986-11-20 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
ES8503669A1 (es) * 1982-07-05 1985-03-01 Erba Farmitalia Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2546166B1 (fr) * 1983-05-19 1985-10-25 Synthelabo Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
SK279476B6 (sk) * 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
BR9408506A (pt) 1997-08-05
MY111623A (en) 2000-09-27
FI113769B (fi) 2004-06-15
CN1048247C (zh) 2000-01-12
PL179448B1 (pl) 2000-09-29
CZ225696A3 (en) 1997-01-15
AU684568B2 (en) 1997-12-18
ZA95692B (en) 1996-07-30
HU221633B1 (hu) 2002-12-28
FI950403L (fi) 1995-08-01
JP2866743B2 (ja) 1999-03-08
HUT75942A (en) 1997-05-28
NZ275151A (en) 1998-02-26
NO963186D0 (no) 1996-07-30
DE69420053D1 (de) 1999-09-16
RU2126404C1 (ru) 1999-02-20
FI950403A0 (fi) 1995-01-30
DK0741724T3 (da) 1999-12-20
WO1995020587A1 (en) 1995-08-03
BR9500380A (pt) 1995-10-17
PE43795A1 (es) 1995-12-09
AU8066394A (en) 1995-08-15
NO309190B1 (no) 2000-12-27
PL315681A1 (en) 1996-11-25
IL112415A0 (en) 1995-03-30
DE69420053T2 (de) 1999-11-25
ATE183184T1 (de) 1999-08-15
HU9602100D0 (en) 1996-09-30
GR3031356T3 (en) 2000-01-31
NO963186L (no) 1996-07-30
US5744483A (en) 1998-04-28
CN1142825A (zh) 1997-02-12
CA2182101C (en) 1999-08-03
IL112415A (en) 1999-07-14
JPH09501698A (ja) 1997-02-18
CO4230161A1 (es) 1995-10-19
CZ286757B6 (en) 2000-06-14
EP0741724A1 (en) 1996-11-13
TW449591B (en) 2001-08-11
EG20672A (en) 1999-11-30
CA2182101A1 (en) 1995-08-03
EP0741724B1 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
ES2134361T3 (es) Compuestos de cromano neuroprotectores.
DE60143493D1 (de) 2-Oxo-1-Pyrrolidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
ES2145915T3 (es) Derivados estereoquimicos de la wortmannina.
DK0907639T3 (da) Polymorfe forbindelser
EP1159952A4 (en) COSMETIC PREPARATIONS
DK0725779T3 (da) Hidtil ukendte (R)-5-Carbamoyl-8-fluor-3-N,N-disubstitueret-amino-3,4-dihydro-2H-1-benzopyraner
DK0888327T3 (da) Benzopyranderivater, som har antagonistisk virkning imod leukotriener
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
TR200001452T2 (tr) Bifenilamidin türevleri.
ATE303362T1 (de) Chalcon-derivate mit antiproliferativer aktivität
BG105710A (en) 5ht1 antagonists for antidepressant therapy
ITMI951073A0 (it) Procedimento per la preparazione di [r-(r*)]-5-(3-clorofenil)-3- [2-(3,4-dimetossifenil)-1-metil]-ossazolidin-2-one"
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
CO5021190A1 (es) Agentes terapeuticos
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
EP1406605A4 (en) CARBAMATES OF 2-HETEROCYCLIC 1,2-ETHANEDIOLS
MXPA02004864A (es) Producto para el blanqueamiento dental.
ES2119454T3 (es) Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina.
ECSP982365A (es) Antagonistas de taquiquinina
ATE230413T1 (de) Pharmazeutisch verträgliche salze von 3-hydroxy- estr-5(10)-en-17-on-3-sulfat die als östrogene aktiv sind
ECSP972237A (es) Derivados de 6,5 heterobiciclicos sustituidos
ECSP972052A (es) Quinoxalinadionas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 741724

Country of ref document: ES